Pulmonary surfactant given prophylactically alleviates an asthma attack in guinea-pigs

Area of Science:

• Pulmonary medicine
• Respiratory physiology
• Allergy and immunology

Background:

• Asthma is characterized by increased airway resistance, potentially linked to surfactant dysfunction.
• Pulmonary surfactant, essential for lung function, may offer therapeutic benefits in respiratory conditions.

Purpose of the Study:

• To investigate the hypothesis that prophylactic pulmonary surfactant instillation can mitigate acute asthma-like symptoms.
• To evaluate the efficacy of calf lung surfactant extract in preventing airway hyperresponsiveness.

Main Methods:

• Twenty-two immunized guinea pigs were challenged, with ten receiving tracheal instillation of calf lung surfactant extract (CLSE).
• Lung function parameters including airway resistance, tidal volume, minute ventilation, and dynamic compliance were monitored post-challenge.
• Blood gas analysis (pCO2 and pO2) was performed to assess respiratory status.

Main Results:

• Surfactant-treated animals (17.5 mg dose) exhibited significantly reduced mortality and less severe lung function impairment compared to controls.
• Surviving animals treated with surfactant showed significantly better lung function (P < 0.01) and blood gas levels (P < 0.05) post-challenge.
• CLSE administration demonstrated a protective effect against allergen-induced airway hyperresponsiveness.

Conclusions:

• Prophylactic airway instillation of pulmonary surfactant can alleviate asthma-like symptoms induced by allergen challenges.
• Pulmonary surfactant shows potential as a therapeutic agent for managing acute respiratory distress in asthma.
• This study supports the role of surfactant replacement therapy in mitigating allergen-induced airway obstruction.